The main challenge facing pharmaceutical research is the creation of new technologies that will give formulations unique properties that overcome the therapeutic constraints of conventional dosage forms, such as adjustable release profiles, flexibility of use, capacity to carry multiple active ingredients, increased patient availability, and compliance. Compared to other forms, these systems offer easier use and application, appropriate consistency and adhesiveness, good flexibility and elasticity and ease of manufacturing

Therapeutic drugs must be delivered via a mechanism that is both efficient and secure. An ideal DDS would have the following characteristics: bioavailability, regulated drug delivery to the body, ease of administration, and cost-effectiveness. Medicated chewing gum should be chewed for a certain period of time to deliver the dose, and then discarded. The IR spectrum of Pure Drug and Physical mixtures was shown in Figure and Characteristics peaks are summarized. The formulation MCG4 was more promising in delivering the drug at required rate and at the same time they maintain the chewing gum like consistency

ACEIs are often prescribed at the lowest rates in previous studies about the use of antihypertensive medications. As long as ACEIs are used appropriately in the black population, they can provide additional cardio- and renal protection benefits. This research is to understand the recent trend of usage of antihypertensive medicines, particularly ACEIs, so as to identify potential changes. The current use of antihypertensive medicine was assessed in 150 randomly selected patients in a 450-bed premier teaching hospital. Among the 150 random cohorts, 119 females (78%) had an average age of 55.7 years. Hypertension was diagnosed in 53.33 percent of cases. From 7.59% and 22%, respectively, to 26.39% and 35.86% (p 0.001), the usage of ACEIs and long-effective CCBs (amlodipine) increased. During the first two months of the study, thiazide diuretics were used 38.04 % and 22.03% less than during the previous year (p<0.0001). ACEIs cause 2 % of adverse drug reactions, while the urea, creatinine and the serum potassium level are only monitored in 35% of cohorts. A total of 26% of cohorts showed potentially harmful interactions between drugs, the most common being ACEIs with NSAIDs (52.03%) and ACEIs with amiloride / hydrochlorothiazide (21.69%). A lot of antihypertensive medicines are now being used in combination with dihydropyridine CCBs and ACEIs. Methyldopa and thiazides are no longer widely used. There appeared to be a greater awareness of long-term benefits of ACEIs in a high-risk group such as black hypertensives.

With the growing prevalence of chronic obstructive pulmonary disease (COPD) and its associated exacerbations, hospital admissions have been increasing and economic impact has been significant. Low dose oral corticosteroids are recommended for treating exacerbations of COPD. The use of systemic corticosteroids in these cases is not adequately reflected in less than 50% of physicians' prescribing practices. Researchers examined the impact of pharmacist-led education interventions on COPD patients with exacerbations treated with systemic corticosteroids. In this retrospective case-control study, patients with COPD exacerbations were treated with systemic corticosteroids in an inpatient family medicine service. Prescribers were provided with pharmacy-led education interventions on systemic corticosteroids for COPD exacerbations. Patients who were retrospectively identified over a three-month period were retrospectively analysed prior to and following an educational intervention. During and after the educational sessions, chart reviews were conducted to evaluate prescribing practices. An educational intervention was also evaluated for its effects on length of stay, adverse events, and treatment costs. There were 25 participants before and 20 participants after intervention. The pharmacist-led interventions did not increase prescriber adherence to guidelines compared to pre-intervention patients. Since guideline adherence did not change statistically significantly, secondary outcomes were not affected. Pharmacist-led didactic education or dissemination of guidelines do not improve systemic corticosteroids in COPD exacerbations